Yingjie Zhang
+
Gender:Male
Education Level:Postgraduate (Doctoral)
Alma Mater:山东大学
Paper Publications
- [21] xuwenfang and Yingjie Zhang. Discovery of a pair of diastereomers as potent HDACs inhibitors: determination of absolute configuration, biological activity comparison and computational study. Rsc Adv., 2013.
- [22] xuwenfang and Yingjie Zhang. Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity. Chem. Biol. Drug Des, 2013.
- [23] xuwenfang and Yingjie Zhang. Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with an Indole-Containing Cap Group. ACS Med. Chem. Lett., 2013.
- [24] xuwenfang , Yingjie Zhang and 曹江营. Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II. BIOORGANIC & MEDICINAL CHEMISTRY Journal, 27, 978, 2019.
- [25] xuwenfang , Yingjie Zhang and 梁学武. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. 《Journal of Medicinal Chemistry》, 62, 3898, 2019.
- [26] xuwenfang , Yingjie Zhang and 陈奉泉. Progress of CDK4/6 inhibitor palbociclib in the treatment of cancer. Anti-cancer agents in medicinal chemistry, 2018.
- [27] xuwenfang , Yingjie Zhang and 赵春龙. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 150, 282, 2018.
- [28] xuwenfang , Yingjie Zhang and 臧杰. Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. Journal of Medicinal Chemistry, 61, 5304, 2018.
- [29] Yingjie Zhang , xuwenfang and 江余祺. Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 143, 334, 2018.
- [30] xuwenfang , Yingjie Zhang and 高倩文. JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases. Current Drug Targets, 19, 487, 2018.